Luma Meds Review

What Luma Meds charges

• Semaglutide: $199/mo — per month, struck through from $249; the same page also prints $140 a month on a three-month plan and $139.99 in its own navigation
• Semaglutide: $232/mo — from, per month
• Tirzepatide: $272/mo — from, per month; the injectable tirzepatide plan card on the same page renders no price at all
• NAD+: $199/mo — per month
• Sermorelin: $180/mo — per month
• Glutathione: $139/mo — per month, with a first month offered free

Its terms contradict its own coverage claim

The product pages say "Available in all 50 states." The terms say "Certain of our Services are currently only available to individuals located in certain states."

Both sentences are published by the same seller and neither is qualified by the other.

No fifty-state claim is credited here as a result. When a seller contradicts itself about coverage, the contradiction is the finding.

The tirzepatide card renders no price

Its plan carousel serves only the semaglutide card in the delivered document, so the injectable tirzepatide plan appears with no figure attached.

That leaves a single navigation entry as the only injectable tirzepatide price published anywhere on the site.

A price that only exists in a menu is not a price a buyer can plan against, and the plan card that should carry it says nothing.

Semaglutide carries three figures on one page

One figure sits on the monthly card, a lower one on the three-month card, and a third in the navigation and footer.

The three-month card also anchors against a struck-through total that three times its own monthly rate does not produce, so that anchor is not filed here.

All three live figures are recorded as published. The site offers no note explaining which a buyer would be charged.

What it does state plainly

Its own words are that "Compounded medications have not been approved by the U.S. Food and Drug Administration" and that the agency "does not review compounded medications for safety, effectiveness, or quality before they are dispensed".

It prices the oral and the injectable forms of the weight-loss molecules separately, and publishes a standing monthly figure for NAD+, sermorelin and glutathione where the numbers hold still.

It names its medical group in its terms, though not a dispensing pharmacy, and those terms carry an unedited reference to a pharmacy network belonging to a different brand — the same leftover two other sellers in this batch carry.

How we verified this

• Read the coverage sentence on the product pages and the coverage sentence in the terms, and recorded both rather than crediting the stronger one.
• Confirmed the injectable tirzepatide plan card carries no figure in the served document, and recorded the navigation entry as the only published price for it.
• Checked the three-month anchor against three times the seller's own monthly rate, found it unsupported, and declined to file it.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand and its legal entity against the live federal warning-letter table through a matcher that normalises both the query and the filed company name before comparing, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run.